Phase 2 COPD Trial, Recruiting NCT07082738 Sponsor: AstraZeneca Condition: COPD
Back to Copd

Phase 2 COPD Trial, Recruiting

NCT07082738
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 40 years of age or older at the time of signing the consent form.
  • People who have had a confirmed diagnosis of COPD (chronic obstructive pulmonary disease) for at least 12 months before joining.
  • People whose lung function test results meet specific measurements related to airflow and lung capacity (confirm exact values with trial site).
  • People who have had at least 2 moderate COPD flare-ups, or at least 1 severe COPD flare-up, in the 12 months before screening.
  • People who have been on a stable inhaled COPD maintenance medication regimen (either two or three inhaled medicines) for at least 3 months before screening.
  • People whose COPD symptom score (called a CAT score) is 10 or higher at the first visit.
  • People who currently smoke or have smoked in the past, with a smoking history of at least 10 pack-years (confirm this measurement with the trial site).
  • People who have been medically stable and free from a COPD flare-up for at least 4 weeks before the first visit, and also free from a flare-up for at least 4 weeks before the randomisation visit.
  • Women who are able to become pregnant must have a negative pregnancy test at the first visit and at the randomisation visit.

Who may not be able to join:

  • People who have a significant lung disease other than COPD, such as asthma, active lung infection, pulmonary fibrosis, cystic fibrosis, lung cancer, or certain other lung conditions.
  • People whose chest scans or X-rays suggest another lung condition that is significantly contributing to their breathing symptoms.
  • People who have an unstable health condition affecting areas such as the heart, digestive system, liver, kidneys, nervous system, blood, hormones, or mental health, or who have a major physical or cognitive impairment.
  • People with significant left heart failure.
  • People who have had a heart attack, unstable chest pain, a heart procedure, uncontrolled irregular heartbeat, cardiomyopathy, significant aortic valve problems, or signs of fluid on the lungs within the past 6 months.
  • People who have pulmonary arterial hypertension (high blood pressure in the lungs).
  • People who have a history of a condition that makes them more prone to infections.
  • People who have been diagnosed with ulcerative colitis, Crohn's disease, or microscopic colitis.
  • People whose blood or laboratory test results are outside the normal range.
  • People who have evidence of active or chronic liver disease.
  • People who have a history of HIV infection or who test positive for HIV.
  • People who have previously had lung volume reduction surgery.
  • People who have had, or have been treated for, cancer within the past 5 years before screening.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dave Singh, MD, Medicines Evaluation Unit, Manchester University NHS Foundations Trust, Manchester, United Kingdom

Phone: 1-877-240-9479

Australian sites

Research Site, Cairns,
Research Site, Nedlands,
Research Site, Norwood,
Research Site, Osborne Park,
Research Site, South Brisbane,
Research Site, Wollongong,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
27 June 2025
Est. completion
5 November 2027

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇱 Chile 🇨🇳 China 🇩🇰 Denmark 🇩🇪 Germany 🇬🇷 Greece 🇭🇺 Hungary 🇮🇳 India 🇮🇹 Italy 🇯🇵 Japan 🇲🇽 Mexico 🇵🇪 Peru 🇵🇱 Poland 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan Turkey (Türkiye) 🇺🇦 Ukraine 🇬🇧 United Kingdom 🇺🇸 United States 🇻🇳 Vietnam

6 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Annualised rate of moderate or severe COPD exacerbations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov